Trimeris has announced it is returning up to $50 million to shareholders and disbursing the rest of its assets by the end of the year. Chief executive Martin Mattingly said the decision is part of Trimeris' "goal of returning value to investors," but a biotech analyst said it signals the gradual liquidation of the biopharmaceutical firm.

Related Summaries